Document is current
Any future updates will be listed below
-
Authors
Chen, Sai
Yang, Jin-Jin
Zhang, Yue
Lei, Lei
Qiu, Di
Lv, Hui-Min
Sun, Zhen-Tao
Hashimoto, Kenji https://orcid.org/0000-0002-8892-0439
Yang, Jian-Jun
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82171189, 82001157, 81971020)
- License Information
-
More Information
Article History
Received: 15 March 2023
Accepted: 11 April 2023
First Online: 18 April 2023
Declarations
:
: Dr. Hashimoto is the inventor of filed patent applications on “The use of <i>R</i>-Ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “<i>R</i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. Dr. Hashimoto has also received speakers’ honoraria, consultant fee, or research support from Abbott, Boehringer-Ingelheim, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience. The other authors have no competing interests.
